… between (i) the growth inhibitory activities for a set of anticancer agents from the panel of
60 … of the tested agents; and (iii) their apparent mechanism of growth inhibitory action (MOA). …

… Despite intensive research aimed at discovering other classes of compounds demonstrating
topoisomerase I inhibitory activity, only a few novel chemotypes have been identified. These …

… Recently, several compounds have been demonstrated to display dual topoisomerase I
and II inhibitory activity. Among them TAS-103 deserves attention. This compound is a novel …

… Abstract: Inhibitors of histone deacetylase (HDAC) are an emerging class of anticancer agents.
They … The enantiomer of 6 has been synthesized but did not show inhibitory activity [46]. …

… for anticancer agents with novel mechanisms of action. Recently identified molecular targets
for new anticancer agents … Of the carbohydrate-processing inhibitors presently available, the …

… CGP 54211 and CGP 53353 (Novartis) are 2 dianilinophthalimides with ATP-competitive
tyrosine kinase inhibitory activity that are only relatively selective for EGFR, since they also …

… caused by BCR-ABL mutations of imatinib, by discovering series of 9-arenethenyl purines
possessing a trans double bond; many of these compounds have the dual inhibitory activity on …

… In general, these inhibitors have nanamolar HDAC inhibitory activity and can have either
irreversible (epoxyketone-based) or reversible mechanisms of action. The macrocyclic peptide …

… Compounds with proven HDAC-inhibitory activity. (a) Scheme showing the general structure
of most of these substances. (b) Examples of chemicals included in the different HDAC …

… anticancer agents based on preclinical evidence of their antiproliferative, proapoptotic,
anti-invasive, and radiosensitizing properties. Inhibition … demonstrated growth inhibitory activity in …